It has also been demonstrated that GRM1 promotes a metabolic phenotype that supports increased glutamate production and autocrine glutamatergic signaling leading to downstream mitogenic signaling; this phenotype may be pharmacologically targeted to reduce glutamate bioavailability and interfere with tumor growth [13]. Here, GRM1 is linked to neoplasm.